Your browser doesn't support javascript.
loading
Effect of Calcium Channel Blockers on Gingival Tissues in Hypertensive Patients in Lagos, Nigeria: A Pilot Study.
Umeizudike, Kehinde Adesola; Olawuyi, Adetokunbo B; Umeizudike, Theophilus I; Olusegun-Joseph, Akinsanya D; Bello, Babawale T.
Afiliação
  • Umeizudike KA; Department of Preventive Dentistry, Faculty of Dental Sciences, College of Medicine University of Lagos, Lagos, Nigeria.
  • Olawuyi AB; Department of Oral and Maxillofacial Pathology/Biology, Lagos University Teaching Hospital, Lagos, Nigeria.
  • Umeizudike TI; Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
  • Olusegun-Joseph AD; Department of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria.
  • Bello BT; Department of Medicine, Faculty of Clinical Sciences, College of Medicine University of Lagos, Idi-Araba, Lagos, Nigeria.
Contemp Clin Dent ; 8(4): 565-570, 2017.
Article em En | MEDLINE | ID: mdl-29326507
ABSTRACT

BACKGROUND:

Long-term treatment of common chronic cardiac conditions such as hypertension with calcium channel blockers (CCBs) has long been associated with gingival hyperplasia. This oral side effect may affect esthetics and function, yet often overlooked and therefore underreported among Nigerians.

AIM:

This study aimed to determine the association of CCBs with gingival overgrowth (GO) in hypertensive patients.

METHODS:

This was a hospital-based, case-control study conducted among 116 hypertensive patients (58 CCB and 58 non-CCB age-matched controls) attending the medical outpatient clinic of a tertiary health institution in Lagos, Nigeria. Data collection tools included interviewer-administered questionnaires and periodontal examination. Sociodemographic details, medical history, and periodontal indices (gingival index, plaque index, class of GO according to drug-induced GO [DIGO] Clinical Index) were recorded.

RESULTS:

The mean age was 59.4 ± 12.6 years, females representing 50.9%. In the CCB group, 39 (67.2%) participants were on amlodipine and 19 (32.8%) were on nifedipine. The mean duration of CCB use was 55.6 ± 53 months. DIGO was higher in CCB (36.2%) than that in non-CCB participants (17.2%) (χ2 = 4.4, P = 0.036). The risk of GO was higher in CCB users (odds ratio [OR] 2.7, [95% confidence interval (CI)] 1.1-6.5). Amlodipine users had higher DIGO (37.5%) than that of nifedipine users (21.1%) (OR 2.3, [95% CI] 1.0-5.3). The predominant class of DIGO among the CCB users was Class 2 DIGO Clinical Index (90.5%).

CONCLUSION:

The study reveals that the risk of GO is nearly three times in CCB than that of non-CCB users and twice higher in amlodipine than nifedipine users in Nigeria.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Contemp Clin Dent Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Nigéria

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Contemp Clin Dent Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Nigéria